Sinopia Biosciences Awarded NIGMS Phase I SBIR

Sinopia Biosciences, a computational biology company in San Diego, received a Phase I Small Business Innovation Research (SBIR) Grant from the National Institute of General Medical Sciences (NIGMS). Entitled "Developing a systems biology platform for predicting drug toxicity and safety", the award will allow Sinopia to expand its therapeutic safety platform to a large number of pharmaceuticals and types of drug side effects.